Search results for "Anti-TNF"

showing 9 items of 19 documents

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Intérêt des méthodes alternatives dans l’évaluation du médicament dans les populations particulières

2020

Well conducted randomized clinical trial is considered gold standard in drug safety and efficacy evaluation. Drug development can be challenging in rare diseases, or in ethically sensitive populations (pregnant women, children, patient with cognitive defect), because of low number of subjects. The low rate of observed events at a sample scale in this population can lead to a biased evaluation of drugs compared to the general population. The aim of this work was to address alternative methods for drug evaluation in particular populations, especially pharmaco-epidemiology on populational database of the SNDS (Système National des Données de Santé). We first evaluate the safety of anti-TNFα in…

Particular populations;Anti-TNFαGrossesseMaladies inflammatoires chroniques intestinales[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyPopulations particulièresPharmaco-EpidemiologyPregnancySndsParticular populationsInflammatory Bowel DiseasesPharmaco-Épidémiologie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Evaluation of Changes in Gut Microbiota in Patients with Crohn’s Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study

2020

Background: Crohn’s disease is believed to result from the interaction between genetic susceptibility, environmental factors and gut microbiota, leading to an aberrant immune response. The objectives of this study are to evaluate the qualitative and quantitative changes in the microbiota of patients with Crohn’s disease after six months of anti-tumor-necrosis factor (anti-TNFα) (infliximab or adalimumab) treatment and to determine whether these changes lead to the recovery of normal microbiota when compared to a control group of healthy subjects. In addition, we will evaluate the potential role of the Faecalibacterium prausnitzii/Escherichia coli and Faecalibacterium prausnitzii/Clostridium…

Project ReportCrohn’s diseasemedicine.medical_specialtyanti-TNFαHealth Toxicology and MutagenesisFaecalibacterium prausnitziilcsh:MedicineDiseaseGut flora03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicinemedicineAdalimumabEscherichia coli and Clostridium coccoides groupHumansProspective Studies030304 developmental biology0303 health sciencesCrohn's diseasebiologygut microbiotabusiness.industryFaecalibacterium prausnitziiTumor Necrosis Factor-alphalcsh:RPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationInfliximabGastrointestinal MicrobiomeDysbiosis030211 gastroenterology & hepatologyCalprotectinbusinessDysbiosismedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

Influenze della terapia con anti-TNF sulla concentrazione delle lipoproteine plasmatiche e sul rischio cardiovascolare nei pazienti affetti da Artrit…

2011

Settore MED/16 - ReumatologiaArtrite Reumatoideanti-TNFlipoproteine plasmatiche
researchProduct

No detection of hidden HBV-DNA in patients with various rheumatic diseases treated anti-TNF agents. A two-year prospective study.

2011

Settore MED/16 - Reumatologiahidden HBV-DNAanti-TNF agents.patients with various rheumatic disease
researchProduct

PReS-FINAL-2088: Risk of severe adverse events in juvenile idiopathic arthritis and pediatric-onset inflammatory bowel disease, treated with anti-tnf…

2013

Introduction: Severe adverse events have been described in children affected by Juvenile Idiopathic Arthritis (JIA) and Inflammatory Bowel Disease (IBD) treated with anti-tnf drugs. Objectives: To define the risk of severe adverse events in patients with JIA and IBD treated with anti-tnf drugs. Methods: This is a retrospective cohort study. All patients with JIA and IBD attending the "IRCCS Burlo Garofolo" of Trieste from 2000 to 2012 were enrolled. They were divided into 2 groups on the basis of the presence or absence of anti-tnf exposure. Severe adverse events were considered the followings: a) infections needing anti-tnf permanent suspension and/or hospitalization; b) autoimmune disease…

medicine.medical_specialtyPathologyPediatric onsetArthritismacromolecular substancesInflammatory bowel diseaseanti-TNF pediatric rheumatology arthritis adverse events inflammatory bowel diseaseRheumatologyinflammatory bowel diseaseInternal medicinemedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child HealthPediatric rheumatologyAdverse effectbusiness.industryanti-TNFmedicine.diseaseadverse eventsdigestive system diseasesRheumatologypediatric rheumatologyarthritisPediatrics Perinatology and Child HealthPoster PresentationTumor necrosis factor alphabusiness
researchProduct

Sinergismo d'azione tra protocollo riabilitativo ed anti-TNFalfa versus terapia biologica

2012

La spondilite anchilosante è una malattia infiammatoria cronica ad eziologia sconosciuta che colpisce prevalentemente lo scheletro assile ma che può coinvolgere anche le entesi periferiche. Presso l'ambulatorio dell'U.O.C. di Riabilitazione dell'A.U.O.P. "Paolo Giaccone" di Palermo, in diciotto mesi (Aprile 2011-Maggio 2012) sono stati arruolati 24 soggetti (6 donne- 18 uomini). affetti da Spondilite Anchilosante HLA B27 diagnosticata secondo i criteri europei. Il presente studio ha mostrato efficacia nel trattamento di pazienti con SA mediante un progetto-programma riabilitativo mirato e specifico per distretto articolare. Svolgere con regolarità e costanza l'esercizio terapeutico in assoc…

riabilitazione spondilite anchilosante anti-TNFalfaSettore MED/34 - Medicina Fisica E Riabilitativa
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct